Abstract
Despite much progress in prostate cancer management, new diagnostic, prognostic and therapeutic tools are needed to predict disease severity, choose among the available treatments and establish more effective therapies for advanced prostate cancer. In the last few years, compelling evidence has documented the role of microRNAs as new broad-spectrum oncogenes or tumour suppressor genes, thus their use as diagnostic, prognostic and therapeutic biomolecules is envisaged. This review extensively and critically summarizes the current knowledge about microRNAderegulation in prostate cancer disease, underlining present limits and future perspectives. © 2010 Society for Endocrinology.
| Original language | English |
|---|---|
| Pages (from-to) | 1-17 |
| Number of pages | 17 |
| Journal | Endocrine-Related Cancer |
| Volume | 17 |
| DOIs | |
| Publication status | Published - 2010 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Adenocarcinoma
- Androgens
- Cancer Research
- Cell Transformation, Neoplastic
- Disease Progression
- Endocrinology
- Endocrinology, Diabetes and Metabolism
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Genes, Tumor Suppressor
- Humans
- Male
- MicroRNAs
- Neoplasm Invasiveness
- Neoplasm Proteins
- Neoplasms, Hormone-Dependent
- Oncology
- Prognosis
- Prostatic Neoplasms
- Proto-Oncogene Proteins c-myc
- RNA, Neoplasm
Fingerprint
Dive into the research topics of 'MicroRNAs and prostate cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver